IRCT20210519051348N1招募中2 期
Evaluation of safety and efficacy of Desferal + Zinc nasal spray to improve clinical and pulmonary symptoms in patients with COVID-19
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Informed and written consent of patient with Coronavirus Confirmation disease by clinical and laboratory signs Serum creatinine less than two Milligram per Deciliter Absence of heart problems( myocarditis- heart failure ) Hemoglobin above 8 Gram per Deciliter Patients admitted to the ward with moderate symptoms 18 to 65 years
排除标准
- •Ferritin lower than 100 milligram per deciliter Diabetes History of blood coagulation problems Pregnancy and Breastfeeding History of neurologic problems History of vision and hearing problems concomitant use of vitamin C Intubated patient History of Desferal or Zinc allergy
研究者
相似试验
招募中
2 期
Desferal in COVID-19IRCT20200506047323N4Bandare-abbas University of Medical Sciences60
已完成
2 期
Deferiprone for the Treatment of Parkinson’s DiseaseEarly-stage Parkinson’s diseaseNeurological - Parkinson's diseaseACTRN12617001578392ApoPharma Inc.36
招募中
3 期
Efficacy and safety of Diphereline and Microreline 3.75mg in breast cancer patientsBreast Cancer.Malignant neoplasm of breastIRCT20201227049847N1Homa Pharmed Company210
进行中（未招募）
1 期
An international open label trial of deferiprone in patients with iron storage brain disorders - an extension to TIRCON2012V1 (a randomised controlled trial of deferiprone in patients with iron storage brain disorders).EUCTR2014-001427-79-GBApoPharma Inc89
进行中（未招募）
1 期
An 18-month extension of an international trial of deferiprone in patients with iron storage brain disordersEUCTR2014-001427-79-DEApoPharma Inc.90